NEW YORK, NY / ACCESSWIRE / September 6, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Abiomed, Inc. (ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws.
To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=abiomed-inc&id=1981 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email firstname.lastname@example.org for information on the class action.
If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) ABIOMED’s revenue growth was in decline; (2) ABIOMED did not have a sufficient plan in place to stem its declining revenue growth; (3) ABIOMED was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, ABIOMED’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
tel: (800) 991-3756
SOURCE: Zhang Investor Law PC
View source version on accesswire.com: